Latest Octagon Capital Advisors LP Stock Portfolio
Octagon Capital Advisors LP Performance:
2024 Q4: 2.04%YTD: -11.71%2023: 6.15%
Performance for 2024 Q4 is 2.04%, and YTD is -11.71%, and 2023 is 6.15%.
About Octagon Capital Advisors LP and 13F Hedge Fund Stock Holdings
In it's latest 13F Holdings report, Octagon Capital Advisors LP reported an equity portfolio of $607.7 Millions as of 31 Dec, 2024.
The top stock holdings of Octagon Capital Advisors LP are APLS, , . The fund has invested 15.8% of it's portfolio in APELLIS PHARMACEUTICALS INC and 9% of portfolio in ARRIVENT BIOPHARMA INC.
The fund managers got completely rid off STRUCTURE THERAPEUTICS INC, ALLOVIR INC (ALVR) and EYEPOINT PHARMACEUTICALS INC (EYPT) stocks. They significantly reduced their stock positions in VERONA PHARMA PLC (VRNA), NUVATION BIO INC (NUVB) and INSMED INC (INSM). Octagon Capital Advisors LP opened new stock positions in SCHOLAR ROCK HLDG CORP (SRRK), MERUS N V (MRUS) and ERASCA INC (ERAS). The fund showed a lot of confidence in some stocks as they added substantially to NEUROGENE INC, DYNE THERAPEUTICS INC (DYN) and TAYSHA GENE THERAPIES INC (TSHA).
The top stock holdings of Octagon Capital Advisors LP are APLS, , . The fund has invested 15.8% of it's portfolio in APELLIS PHARMACEUTICALS INC and 9% of portfolio in ARRIVENT BIOPHARMA INC.
The fund managers got completely rid off STRUCTURE THERAPEUTICS INC, ALLOVIR INC (ALVR) and EYEPOINT PHARMACEUTICALS INC (EYPT) stocks. They significantly reduced their stock positions in VERONA PHARMA PLC (VRNA), NUVATION BIO INC (NUVB) and INSMED INC (INSM). Octagon Capital Advisors LP opened new stock positions in SCHOLAR ROCK HLDG CORP (SRRK), MERUS N V (MRUS) and ERASCA INC (ERAS). The fund showed a lot of confidence in some stocks as they added substantially to NEUROGENE INC, DYNE THERAPEUTICS INC (DYN) and TAYSHA GENE THERAPIES INC (TSHA).
Octagon Capital Advisors LP Annual Return Estimates Vs S&P 500
Our best estimate is that Octagon Capital Advisors LP made a return of 2.04% in the last quarter. In trailing 12 months, it's portfolio return was -11.71%.
New Buys
| Ticker | $ Bought |
|---|---|
| scholar rock hldg corp | 21,091,400 |
| merus n v | 12,951,400 |
| erasca inc | 12,893,400 |
| syndax pharmaceuticals inc | 11,950,900 |
| kalvista pharmaceuticals inc | 11,603,900 |
| allovir inc | 4,710,300 |
| atyr pharma inc | 3,258,000 |
New stocks bought by Octagon Capital Advisors LP
Additions
| Ticker | % Inc. |
|---|---|
| neurogene inc | 1,920 |
| dyne therapeutics inc | 154 |
| taysha gene therapies inc | 128 |
| cogent biosciences inc | 111 |
| gossamer bio inc | 99.72 |
| perspective therapeutics inc | 62.05 |
| pharvaris n v | 25.39 |
| dianthus therapeutics inc | 20.81 |
Additions to existing portfolio by Octagon Capital Advisors LP
Reductions
| Ticker | % Reduced |
|---|---|
| verona pharma plc | -68.87 |
| nuvation bio inc | -24.39 |
| insmed inc | -24.00 |
| bridgebio pharma inc | -20.00 |
| centessa pharmaceuticals plc | -0.94 |
Octagon Capital Advisors LP reduced stake in above stock
Sold off
| Ticker | $ Sold |
|---|---|
| tenaya therapeutics inc | -4,972,070 |
| ventyx biosciences inc | -5,212,630 |
| structure therapeutics inc | -52,580,200 |
| eyepoint pharmaceuticals inc | -8,737,090 |
| century therapeutics inc | -1,140,270 |
| mineralys therapeutics inc | -7,266,000 |
| black diamond therapeutics i | -2,583,900 |
| cybin inc | -4,352,510 |
Octagon Capital Advisors LP got rid off the above stocks
Sector Distribution
Octagon Capital Advisors LP has about 77.4% of it's holdings in Healthcare sector.
| Sector | % |
|---|---|
| Healthcare | 77.4 |
| Others | 22.6 |
Market Cap. Distribution
Octagon Capital Advisors LP has about 3.9% of it's portfolio invested in the large-cap and mega-cap stocks.
| Category | % |
|---|---|
| SMALL-CAP | 38.7 |
| MID-CAP | 27.8 |
| UNALLOCATED | 22.6 |
| MICRO-CAP | 5.7 |
| LARGE-CAP | 3.9 |
| NANO-CAP | 1.4 |
Stocks belong to which Index?
About 33.8% of the stocks held by Octagon Capital Advisors LP either belong to S&P 500 or RUSSELL 2000 index.
| Index | % |
|---|---|
| Others | 66.2 |
| RUSSELL 2000 | 33.8 |
Octagon Capital Advisors LP Holdings Map
This heatmap illustrates the top 50 positions within the fund's portfolio.
Current Stock Holdings of Octagon Capital Advisors LP
Octagon Capital Advisors LP has 31 stocks in it's portfolio. About 60.5% of the portfolio is in top 10 stocks. CRBP proved to be the most loss making stock for the portfolio. VRNA was the most profitable stock for Octagon Capital Advisors LP last quarter.
Last Reported on: 14 Feb, 2025| Ticker | Namesorted ascending | % Portfolio | Shares Held | $ Value | Type | % Change | Options | |
|---|---|---|---|---|---|---|---|---|
| ALVR | allovir inc | 0.78 | 487,609 | 4,710,300 | new | |||
| ALVR | allovir inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| ANNX | annexon inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| APLS | apellis pharmaceuticals inc | 15.79 | 3,006,980 | 95,952,700 | unchanged | 0.00 | ||
| AUTL | autolus therapeutics plc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| AVTE | aerovate therapeutics inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| BBIO | bridgebio pharma inc | 1.99 | 441,600 | 12,117,500 | reduced | -20.00 | ||
| BDTX | black diamond therapeutics i | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| CNTA | centessa pharmaceuticals plc | 5.49 | 1,993,050 | 33,383,600 | reduced | -0.94 | ||
| COGT | cogent biosciences inc | 3.55 | 2,763,000 | 21,551,400 | added | 111 | ||
| CRBP | corbus pharmaceuticals hldgs | 2.16 | 1,115,000 | 13,157,000 | unchanged | 0.00 | ||
| CYBN | cybin inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| DYN | dyne therapeutics inc | 2.59 | 668,000 | 15,738,100 | added | 154 | ||
| ERAS | erasca inc | 2.12 | 5,136,800 | 12,893,400 | new | |||
| EYPT | eyepoint pharmaceuticals inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| GOSS | gossamer bio inc | 2.73 | 18,350,000 | 16,599,400 | added | 99.72 | ||
| INSM | insmed inc | 3.77 | 332,000 | 22,921,300 | reduced | -24.00 | ||
| IPSC | century therapeutics inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| KALV | kalvista pharmaceuticals inc | 1.91 | 1,370,000 | 11,603,900 | new | |||
| LIFE | atyr pharma inc | 0.54 | 900,000 | 3,258,000 | new | |||